Time to initial highly active antiretroviral therapy discontinuation and its predictors among HIV patients in Felege Hiwot comprehensive specialized hospital: a retrospective cohort study

Table 3 Cox regression analysis between different predictors and time to initial highly active antiretroviral therapy discontinuation among HIV patients in Felege hiwot comprehensive specialized hospital, northwest Ethiopia, 2014–2019

Variable		Survival status		CHR (95% CI)	P-value	AHR (95% CI)	P-value
Variable		Event	Censored	CHR (95% CI)	P-value	AHR (95% CI)	P-value
Sex	Male	69	101	1
Sex	Female	75	173	0.54 (0.38–0.74)	0.000
Occupation	Civil servant	40	57	1
	Merchants	29	53	0.8 (0.5–1.3)	0.39
	Farmer	10	39	0.6 (0.32–1.3)	0.2
	Dailey laborer	9	44	0.29 (0.14–0.61)	0.001
	Others⃰	56	81	1.0 (0.68–1.5)	0.87
ART pills /day	1 pill/day	79	232	1		1
ART pills /day	> 1 pill/day	65	42	7.5 (5.2–10.8)	0.000	4.1 (2.7–6.1)	< 0.001
Adherence status	Good	132	235	1
	Fair	1	15	0.19 (0.026–1.34)	0.97
	Poor	11	24	1.3 (0.7–2.4)	0.3
Base line CD4 count	< 100cell/mm³	67	21	6.6 (4.0–10.9)	0.000	2.6 (1.5–4.7)	0.001
	100–199cell/mm³	28	50	2.6 (1.4–4.7)	0.000	2.3 (1.3–4.3)	0.004
	200–349cell/mm³	29	68	2.2 (1.2–3.9)	0.08	1.7 (1.0–3.1)	0.065
	> = 350cells/m m3	20	135	1		1
Co-medication other than CPT	No	66	232	1
Co-medication other than CPT	Yes	78	42	2.7 (1.9–3.8)
Baseline WHO clinical stage	I	29	157	1		1
	II	32	45	2.5 (1.5–4.2)		1.2 (0.7–2.0)	0.57
	III	27	49	3.5 (1.9–5.6)		2.6 (1.5–4.5)	0.001
	Iv	56	23	6.0 (3.8–9.5)		2.68 (1.6–4.4)	< 0.001
Tuberculosis infection	No	70	265	1
Tuberculosis infection	Yes	74	9	5.3 (3.8–7.4)		2.3 (1.6–3.4)	< 0.001
Substance use	No	129	260	1
Substance use	Yes	15	14	1.57 (0.92–2.69)

ISSN: 1742-6405